Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain

Advances in recombinant antibody technology and protein engineering have provided the opportunity to reduce antibodies to their smallest binding domain components and have concomitantly driven the requirement for devising strategies to increase serum half-life to optimise drug exposure, thereby incr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Müller, Mischa R., Saunders, Kenneth, Grace, Christopher, Jin, Macy, Piche-Nicholas, Nicole, Steven, John, O’Dwyer, Ronan, Wu, Leeying, Khetemenee, Lam, Vugmeyster, Yulia, Hickling, Timothy P., Tchistiakova, Lioudmila, Olland, Stephane, Gill, Davinder, Jensen, Allan, Barelle, Caroline J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Landes Bioscience 2012
Konular:
Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3502234/
https://ncbi.nlm.nih.gov/pubmed/23676205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.22242
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller